Skip to main content
TipRanks
Go Ultimate75% OFF

MicroPort NeuroTech Limited (2172) Drug Pipeline

3 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Experimental Device A, A Self-Expanding Rapamycin Target-Eluting Stent (Microport Neurotech, Shanghai, China), Experimental Device B, A Balloon-Expandable Rapamycin Target-Eluting Stent (Microport Neurotech, Shanghai, China), Apollo® Intracranial Artery Stent System, A Balloon-Expandable Bare-Metal Stent (Microport Neurotech, Shanghai, China),Intracranial ArteriosclerosisPhase IIINot Yet RecruitingA Randomized Trial of the Rapamycin Target Eluting Stent for the Treatment of Symptomatic Cerebral Artery Atherosclerotic Disease(TARGET-DREAM)Mar 27, 2025

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does MicroPort NeuroTech Limited (HK:2172) have in its pipeline
MicroPort NeuroTech Limited HK:2172 is currently developing the following drugs: Experimental Device A, A Self-Expanding Rapamycin Target-Eluting Stent (Microport Neurotech, Shanghai, China), Experimental Device B, A Balloon-Expandable Rapamycin Target-Eluting Stent (Microport Neurotech, Shanghai, China), Apollo® Intracranial Artery Stent System, A Balloon-Expandable Bare-Metal Stent (Microport Neurotech, Shanghai, China),. These drug candidates are in various stages of clinical development as the company works toward FDA approval.